Selank and Semax occupy an unusual position in the research peptide landscape. Both were developed at Russian research institutions, both have regulatory approval for specific uses in Russia and Eastern Europe, and both have generated a body of published research that spans several decades. Yet outside of their home research tradition they remain relatively unfamiliar, and the English-language literature on them is considerably thinner than their scientific profiles would suggest warranted. Recent research activity suggests that is beginning to change, with new investigative directions emerging across anxiety, neuroprotection, immune function, and brain imaging contexts.
Contents
Semax: Current Investigative Directions
Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone, specifically the ACTH 4-10 sequence. It is registered for clinical use in Russia for ischemic stroke therapy, giving it a more developed human research record than most compounds in the research peptide category. Recent research has been examining its potential relevance to neurological conditions beyond stroke.
Semax and Parkinson’s Disease Research
A 2025 qualitative review examined the published preclinical evidence for Semax as a potential research tool in Parkinson’s disease models. The review was motivated by Semax’s established ability to modulate monoaminergic systems, which is relevant because Parkinson’s disease involves the progressive loss of dopaminergic neurons. The reviewers examined rodent studies measuring dopamine levels, serotonin responses, and locomotor outcomes after Semax administration. The findings were mixed: most studies agreed that Semax reduces anxiety-related behavior, but evidence for direct effects on striatal dopamine or locomotor improvement was inconsistent across studies. One study reported that at higher doses, a significant increase in motor performance was observed, while another found no changes in tissue or extracellular dopamine when Semax was administered alone. However, when Semax was given prior to d-amphetamine, it markedly amplified dopamine release and locomotor activity, suggesting interactions with dopaminergic signaling that are dose- and context-dependent.
Neurotransmitter and BDNF Interactions
Ongoing research has continued to examine Semax’s interactions with brain-derived neurotrophic factor (BDNF) signaling, which has been a consistent theme in the Semax literature. BDNF plays a central role in neuronal survival, plasticity, and the formation of new synaptic connections, and compounds that upregulate BDNF signaling are of considerable interest in neuroprotection research. Published studies examining gene expression responses in ischemic rat brain tissue have found that Semax predominantly enhances the expression of genes related to the immune system in the early post-ischemic period, with effects on immune-related signaling expanding considerably at twenty-four hours after injury. This transcriptomic work suggests that Semax’s neuroprotective effects may operate substantially through modulation of the neuroinflammatory response rather than direct neuroprotective signaling alone.
Selank: Anxiety, Immunity, and Brain Connectivity
Selank is a synthetic heptapeptide analogue of tuftsin, a naturally occurring tetrapeptide derived from immunoglobulin G. Its research history has emphasized anxiolytic properties and immunomodulatory effects, and recent work has extended into brain imaging approaches.
Functional Connectivity Research in Human Subjects
A functional MRI study examined the effects of both Selank and Semax on whole-brain resting-state functional connectivity in fifty-two healthy participants. Participants underwent resting-state fMRI scanning before administration and then five and twenty minutes after receiving either Semax, Selank, or placebo by injection. The study focused on regions of interest including the amygdala, a key region for anxiety regulation, and the dorsolateral prefrontal cortex, which is involved in executive functions including working memory. The findings revealed differences in functional connectivity between the right amygdala and regions in the temporal cortex between the Selank and Semax groups and the placebo group. The researchers described this as providing the first characterization of both shared and distinct effects of these two peptides on amygdala-temporal connectivity, an approach that offers a more mechanistically specific window into how these compounds interact with brain networks than behavioral measures alone can provide.
Immune Modulation Under Stress Conditions
Research examining both Selank and Semax in a social stress model in laboratory animals found that both compounds functioned as effective immunocorrectors, restoring cellular and humoral immunogenesis reactions and phagocytic activity of neutrophils that had been disrupted by stress exposure. This work extends the immunomodulatory research profile of both peptides beyond their neurological contexts, suggesting that the interaction between their neuropeptide activity and immune system regulation may be a meaningful and understudied aspect of how they function in living biological systems. Stress-induced immune dysregulation is an area of growing research interest, and compounds that modulate both neural and immune responses to stress represent potentially useful research tools for studying these interconnected systems.
Regulatory Context and Research Availability
Both Selank and Semax are registered medications in Russia, which gives them a regulatory status that most research peptides do not have. Semax is available in Russian and Ukrainian pharmacies and has been studied in human clinical contexts for stroke. This clinical background provides a human safety profile that pure research compounds lack, though the studies establishing that profile were conducted primarily in Russian research settings and have limited independent replication in Western literature.
Outside of Russia and Eastern Europe, both compounds are available through research peptide channels as research use only compounds without approval for therapeutic use in most countries. The divergence between their regulatory status in one part of the world and their unregulated research status elsewhere is a feature of the global research peptide landscape that applies to several compounds with Eastern European development histories.
Frequently Asked Questions About Selank and Semax Research
- What are Selank and Semax and how are they related?
- Selank and Semax are both synthetic heptapeptides developed at the Institute of Molecular Genetics in Russia. Semax is derived from a fragment of adrenocorticotropic hormone and has been studied primarily for neuroprotective and nootropic properties. Selank is a synthetic analogue of the naturally occurring peptide tuftsin and has been studied primarily for anxiolytic and immunomodulatory effects. Both are registered for clinical use in Russia, and both are available as research use only compounds through research peptide channels in most other countries.
- What did recent fMRI research find about Selank and Semax effects on the brain?
- A functional MRI study in fifty-two healthy participants examined resting-state brain connectivity before and after administration of Selank, Semax, or placebo. The study found differences in functional connectivity between the right amygdala and temporal cortex regions in the Selank and Semax groups compared to placebo, and identified both shared and distinct connectivity effects for the two compounds. This neuroimaging approach provides mechanistic specificity about how these peptides interact with brain networks that behavioral outcome measures alone cannot offer.
- What is being investigated about Semax and Parkinson’s disease?
- A 2025 qualitative review examined the preclinical evidence for Semax as a research tool in Parkinson’s disease models, motivated by the peptide’s established interactions with monoaminergic systems relevant to dopaminergic neurobiology. The review found mixed evidence: consistent anxiolytic effects across studies but inconsistent direct effects on striatal dopamine or locomotor function. One study reported motor performance improvements at higher doses, and another found that Semax amplified dopamine release when administered prior to d-amphetamine, suggesting context-dependent interactions with dopaminergic pathways that warrant further investigation.
- Are Selank and Semax safe for human use?
- Both compounds are approved for specific medical uses in Russia and have been used clinically in that context, providing a human safety profile that most research peptides lack. However, outside of Russia they are not approved for therapeutic use by regulatory bodies including the FDA. The clinical data supporting their safety in Russian medical practice does not constitute the type of rigorously controlled clinical trial evidence that Western regulatory bodies require for approval. Outside of approved clinical contexts, they should be treated as research use only compounds.